Lipigon Pharmaceuticals

Lipigon Pharmaceuticals AB is a Swedish clinical-stage pharmaceutical company based in Umeå. It develops medicines for lipid-related diseases, with a focus on disorders of triglyceride and fat metabolism where treatment options are limited or absent.

— Lipigon Pharmaceuticals
%
Lead drug candidate0% Lipisense® is the company's most advanced program, aimed at lowering triglycerides in lipid-related disease.
Clinical development programs0% Human-stage development work for drug candidates targeting lipid-related diseases.
Preclinical pipeline0% Earlier-stage research programs focused on fat metabolism and related disease mechanisms.
Partnering and licensing0% Out-licensing and collaboration arrangements with larger pharmaceutical companies.

Lipigon does not sell a broad commercial product portfolio; its direct counterparties are mainly pharmaceutical...

  • Pharmaceutical licensing partnersprimary

    Large drug companies that may license Lipigon assets to fund development and commercialization.

  • Research and clinical collaboratorsprimary

    Contract research and clinical partners that execute studies and generate development data.

  • Patients with lipid-related diseasessecondary

    Future end users of Lipisense® and other candidates targeting triglyceride and fat metabolism disorders.

  • Healthcare providers and payerssecondary

    Hospitals, specialists, and payers that would adopt approved therapies if they reach market.

Lipigon is headquartered in Umeå, Sweden, with administrative presence also referenced in Stockholm...

  • •Headquartered in Umeå, Sweden
  • •Administrative address referenced in Stockholm
  • •Research and development centered in Sweden
  • •Target markets include major global pharmaceutical regions
  • •Commercial opportunity is international rather than local

Lipigon's strategy is to build a portfolio of lipid-related drug candidates and advance them through clinical...

01
Advance Lipisense®short-term

The lead candidate is the main value driver and the clearest path to clinical proof of concept.

02
Use patient stratificationmedium-term

Genetically defined or advanced disease segments can reduce study size and improve signal detection.

03
Partner for commercializationmedium-term

Large pharmaceutical partners can provide development funding, sales reach, and regulatory scale.

Lipigon's value creation depends on successful preclinical and clinical development, which is inherently uncertain and...

high

Clinical and preclinical failure

Drug candidates can work in early studies but fail in later human trials.

Scope
Lipisense® and other pipeline projects
Materiality
high
high

Key-person dependence

A small clinical-stage company relies heavily on specialized scientific and managerial talent.

Scope
Research, development, and partner management
Materiality
high
high

Regulatory and approval risk

Drug development requires successful regulatory review, and approvals may be delayed or limited.

Scope
Clinical programs and future market access
Materiality
high
medium

Patent and litigation risk

Biopharma companies face disputes over intellectual property and freedom to operate.

Scope
Drug candidates and partnering value
Materiality
medium
medium

Competitive pressure

Larger companies can outspend smaller firms in R&D, regulatory work, and commercialization.

Scope
Lipid disorder treatment market
Materiality
high
Milestone revenue recognition
Reported revenue may depend on contract events rather than steady sales
Operating lease commitments
Useful for assessing cash obligations and overhead
Equity instruments and warrants
Important for per-share analysis and financing assessment
Tax loss carryforwards
Relevant to long-term tax planning and balance sheet valuation

Lipocine Inc.

LPCN · Pharmaceutical Preparations

RHYTHM PHARMACEUTICALS, INC.

RYTM · Pharmaceutical Preparations

Aligos Therapeutics, Inc.

ALGS · Biological Products, (No Diagnostic Substances)

LIPELLA PHARMACEUTICALS INC.

LIPO · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

LEXICON PHARMACEUTICALS, INC.

LXRX · Pharmaceutical Preparations

: 11/08/2026